{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'Table 3:', 'Schedule of Assessments: Part 2 of Study BCX7353-301', 'Part 2', 'Assessment', 'Double-Blind, Active Study Drug Administration', 'Week 26b', 'Week 28', 'Week 32', 'Week 36', 'Week 48', 'Week 52', 'Day 183', 'Day 197', 'Day 225', 'Day 253', 'Week 40', 'Week 44', 'Day 337', '(Day 365)', '2 days', '2 days', '2 days', '2 days', '7 days', '2 days', 'In-clinic evaluation', 'X', 'X', 'X', 'X', 'X', 'X', 'Telephone contact', 'X', 'X', 'Subject weight', 'X', 'X', 'X', 'X', 'X', 'Physical examinationd', 'X', 'X', 'X', 'X', 'X', 'Urine pregnancy test', 'X', 'X', 'X', 'X', 'X', 'Vital signse', 'X', 'X', 'X', 'X', 'X', 'Safety laboratory evaluations', 'Xb', 'X', 'X', 'X', 'X', 'X', 'Troponin I & troponin T', 'X', 'X', 'X', 'X', 'X', 'NGAL', 'X', 'X', 'X', 'X', 'X', 'CK-MB', 'X', 'X', 'X', 'X', 'X', 'Urinalysis', 'Xb', 'X', 'X', 'X', 'X', 'X', '12-lead ECGR', 'X', 'X', 'X', 'X', 'X', 'EQ-5D-5Lh,', 'X', 'X', 'X', 'X', 'X', 'AE-QoL, TSQM, and WPAI\u00b9', 'X', 'X', 'X', 'X', 'X', 'Concomitant medications', 'AEs', 'e-diary instruction/review', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'e-diary daily completion', 'Study drug dosing\u00b9', 'Investigator review of angioedema', 'eventsm', 'Study drug accountability/ dispensing', 'X', 'X', 'X', 'X', 'X', 'Plasma for BCX7353 concentration and', 'X', 'X', 'X', 'X', 'X', 'PD analysis\"', 'Abbreviations: AE = adverse event; AE-QoL = angioedema quality of life questionnaire; ALP = alkaline phosphatase; ALT = alanine transferase; AST aspartate', 'aminotransferase; CK-MB = creatine kinase MB isoenzyme; ECG = electrocardiogram; eCRF = case report form; e-diary = electronic diary;', 'EQ-5D-5L = EuroQoL 5-dimensional, 5-level questionnaire; GGT = gamma-glutamyltransferase HAE = hereditary angioedema; NGAL = neutrophil', \"gelatinase-associated lipocalin; PD = pharmacodynamics; PK = pharmacokinetics; QoL = quality of life; QTcF = QT interval corrected by Fridericia's formula;\", 'TSQM = Treatment Satisfaction Questionnaire for Medication; WPAI = Work Productivity and Activity Impairment Questionnaire.', 'a', 'Period 2 study drug is to be initiated upon administration of study drug, dispensed at the Week 24 visit.', '59']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'b', 'The Week 26 visit will consist of monitoring liver function tests only (ALT, AST, GGT, total and direct bilirubin, ALP); urine and additional', 'tubes', 'of', 'blood', 'will be required to accommodate possible reflex testing for abnormal GGT, AST, or ALT (see Table 5). If preferred by the subject and clinical site,', 'laboratory values may be drawn and resulted locally, with results entered into the eCRF.', 'The investigator (or designee) must call and talk to the subject during Weeks 40 and 44; alternative forms of interactive communication such as returned', \"email and cellular text correspondence are acceptable. During all calls, the investigator (or designee) will assess the subject's overall wellbeing, discuss\", 'compliance (if applicable), proper recording of angioedema event details (if applicable), or any usability issues with the e-diary. The phone', 'call', 'may', 'be', \"omitted if the subject records an angioedema event as the investigator must call and discuss details of the event (see Footnote 'm').\", 'd', 'Abbreviated physical examinations targeted to signs and symptoms will be performed at post-baseline visits.', 'e', 'To include blood pressure and pulse rate. Prior to obtaining vital signs, subjects should rest in a supine position for at least 5 minutes.', 'f', 'Table 5 lists parameters to be assessed.', 'g', 'ECGs may be single assessments. Prior to obtaining an ECG, subjects should rest quietly in a supine position for at least 10 minutes. ECGs should be', 'obtained prior to any blood sampling. An ECG should be repeated for a change from baseline in QTcF > 60 msec or a QTcF interval > 500 msec.', 'h', 'The EQ-5D-5L will be administered 1 to 2 X at Weeks 28, 32, 36, 48, and 52. The subject will fill out the first EQ-5D-5L at baseline and on-study to', 'describe his or her current health state today as instructed per the instrument. The subject will also fill out a second EQ-5D-5L based on a recollection of his', 'or her health state during an average angioedema event experienced since the last study visit. If the subject has not had an angioedema event since the last', 'study visit, the subject is not required to fill out the second, angioedema event-related EQ-5D-5L.', 'i', 'Where possible, QoL and health outcome questionnaires should be collected as the first assessments at a visit. Additional information about long-term', 'experience on study may be collected at Week 52.', 'j', 'Any issues (including mediocre or poor compliance) warranting e-diary re-education should occur on an as-needed basis.', 'k', \"At any time the e-diary is in a subject's possession, they will enter angioedema events (attacks, symptoms or swelling due to HAE)\", 'and', 'relevant', 'details', 'and', 'dosing information (as applicable) at least once per day.', '1', 'Study drug should be taken at approximately the same time each day, with whichever meal is typically the largest of the day. Subjects are not required to', 'take their doses at clinic visits.', 'm', 'An independent expert will review the e-diary record in conjunction with investigator-collected details of all angioedema events that occur from screening', 'through follow-up during Parts 1 and 2 and either confirm or reject each event as an angioedema event. For all angioedema events that are recorded, subjects', 'will be contacted within approximately 2 business days of the end of the angioedema event to discuss the clinical characteristics of the angioedema event,', 'any questions the investigator has on the entered data, or to gain additional details on the event that are not included in the e-diary that the investigator deems', 'important to clinically evaluate the event, as applicable. The investigator-collected information, in conjunction with the e-diary', 'record,', 'will', 'be', 'used', 'by', 'an', 'independent expert to verify or reject each event recorded in the e-diary as a confirmed angioedema event. The investigator e-diary data review and subject', 'contact summaries will be documented in the source records and made available to an independent expert for their verification (confirmation or rejection) of', 'the event.', 'n', 'PK and PD blood samples will be drawn on all subjects with no particular relationship to the timing of study drug dosing. The investigator (or designee)', \"must ensure that the time of the last dose prior to PK and PD draw is recorded in the subject's e-diary (this may also be captured in the eCRF).\", '60']\n\n###\n\n", "completion": "END"}